NEW YORK (GenomeWeb) – Biomarx Therapeutics is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by the first quarter of 2019.

Towia Libermann, a company cofounder and scientific advisor for the Harvard University spinout, said in an interview that Biomarx has raised $200,000 since it was established last year, By the end of 2017, the firm hopes to close a Series A round of about $3.5 million to continue test development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.